<DOC>
	<DOCNO>NCT00287573</DOCNO>
	<brief_summary>The objective study evaluate safety effectiveness TAXUS Express2 Paclitaxel-Eluting Coronary Stent System compare brachytherapy patient experience in-stent restenosis .</brief_summary>
	<brief_title>Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent Treatment In-Stent Restenosis</brief_title>
	<detailed_description>Percutaneous approach in-stent restenosis ( ISR ) include balloon angioplasty alone , rotational atherectomy , cut balloon angioplasty , directional coronary atherectomy , excimer laser angioplasty , placement second stent combination thereof , intra-coronary brachytherapy . Of , brachytherapy show reduce recurrent restenosis PCI ISR , - consider standard care . Logistical consideration establish maintain radiation program limit widespread availability modality . These consideration include need involvement radiation oncologist , physicist , safety officer ; nuclear licensing requirement ; need increase shield safety training ; equipment procedural complexity ; well increase procedural time cost . Furthermore , recurrent ISR brachytherapy may still occur . Stent base drug delivery treatment ISR hold promise much simpler , safer potentially effective alternative brachytherapy . This prospective , randomize ( 1:1 ) , open-label , multicenter , safety efficacy trial treatment in-stent restenosis . The primary objective demonstrate superior non-inferior 9-month target vessel revascularization ( TVR ) rate TAXUS-SR stent compare intra-coronary brachytherapy ( beta source ) .</detailed_description>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Cumulative target lesion length &lt; /= 46 mm ( visual estimate ) . Reference vessel diameter ( RVD ) &gt; /= 2.5 &lt; /= 3.75 mm ( visual estimate ) Left ventricular ejection fraction ( LVEF ) &gt; /= 25 % Any previous plan treatment nonstudy antirestenotic drugcoated drugeluting coronary stent target vessel . ( Note : previous plan treatment heparin phosphorylcholine coat stent acceptable , long , procedure nonstudy stent meet protocol define criterion nontarget lesion intervention . ) Previous plan treatment intracoronary brachytherapy ( gamma beta source ) target vessel Previous external radiotherapy heart target vessel area Known genetic radiation sensitivity disorder ( i.e . ataxiatelangiectasia , etc . ) Side branch target lesion include ostial narrow &gt; /= 50 % diameter stenosis ( DS ) &gt; /= 2.0 mm diameter Target lesion previously treat ISR placement second stent ( ) , cover &gt; /= 50 % original stent length ( true `` stent sandwich '' ) Target vessel pretreated unapproved device , directional rotational coronary atherectomy , laser , transluminal extraction catheter immediately prior delivery randomize treatment ( stent placement intracoronary brachytherapy ) Recent myocardial infarction ( MI ) ( symptom onset &lt; /= 72 hour prior randomization ) CKMB &gt; 2x local laboratory 's upper limit normal ( ULN ) ( refers measure value day index procedure draw per protocol ) Anticipated treatment warfarin period 6 month post index procedure Anticipated treatment paclitaxel , oral rapamycin colchicine period 9 month post index procedure Planned use study stent nonstudy stent ( i.e. , commercial stent ) treatment target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>